Inclusion Criteria:

• Age up to 70 years.
• Patients with lymphoid malignancies (primary refractory or recurrent) beyond first remission or unresponsive to therapy and not eligible for protocols of higher priority. Patients should have had at least a partial remission or have stable disease with prior chemotherapy. Patients with bulky disease (greatest dimension > 5 cm by radiographic or clinical examination are not eligible).
• Adequate renal function, as defined by serum creatinine <1.8 mg/dL.
• Adequate hepatic function, as defined by SGPT <3 X upper limit of normal; serum bilirubin and alkaline phosphatase <3 X upper limit of normal.
• Adequate pulmonary function with FEV1, FVC and DLCO >35% of expected corrected for hemoglobin. Exceptions may be allowed for patients with pulmonary involvement after discussing with PI.
• Adequate cardiac function with left ventricular ejection fraction >35%. No uncontrolled arrhythmias or symptomatic cardiac disease.
• Zubrod performance status <2
• Patients must have an HLA matched, or one A, B, C, DR, or DQ mismatched related or unrelated donor (by high resolution typing). Donor must be willing to donate peripheral blood progenitor cells.
• Patient should be willing to participate in the study by providing written consent.
• Negative beta HCG test in a woman of child bearing potential (defined as not post menopausal for 12 months or no previous surgical sterilization).

Exclusion Criteria:

• Patients with active CNS disease.
• Evidence of acute or chronic active hepatitis or cirrhosis.
• Uncontrolled infection, including Hepatitis B, C, HIV or HTLV-1 infection.